Breast cancer programs rarely struggle because testing is unavailable. They struggle because testing is not consistently embedded into clinical pathways with the same rigor as imaging, pathology sign‑out, surgery scheduling, or treatment planning. For health systems, especially those operating across distributed networks, the challenge is not whether testing matters, but whether it is operationalized early enough, owned clearly enough, and returned in time to influence decisions. Pathway discipline is what turns precision oncology from intent into impact.
Early-stage decision-making succeeds or fails on timing
In early-stage breast cancer, small operational differences between sites can quickly translate into differences in care. For eligible patients with hormone receptor‑positive, HER2‑negative invasive disease, genomic assays such as the Oncotype DX Breast Recurrence Score® test can help inform distant recurrence risk and whether chemotherapy is likely to add benefit. But that value depends on timing. The patient must be identified as eligible, the specimen must move without delay, and the result must return before the treatment plan is decided. When that sequence relies on individual memory rather than standardized workflow, the same evidence can produce different care across providers.
Germline testing adds another layer. As hereditary assessment becomes routine in breast cancer care, the operational question is not just which patients should be tested, but how results are integrated into surgical planning, systemic treatment decisions, future screening, and family risk management. Whether a system uses the Riskguard® test or another hereditary testing approach, the need is the same: clear rules for consent, ordering, routing, counseling, and follow‑up.
For many health systems, this is where pathway discipline either strengthens decision‑making or exposes fragmentation. Stronger programs define eligibility in advance, assign ownership across surgery, pathology, navigation, genetics, and medical oncology, and ensure testing occurs early enough to influence care.
New tools matter, but governance matters more
As oncology programs look beyond the initial treatment decision, newer testing approaches are creating both opportunity and complexity. Tumor‑informed ctDNA assays such as the Oncodetect® test are drawing interest for monitoring molecular residual disease, signs of recurrence, or treatment response. “These three tools can form a longitudinal, multi-biomarker strategy: germline Riskguard testing to define inherited risk and inform surgical strategy, Oncotype DX® testing to define who may benefit from adjuvant chemotherapy, and Oncodetect MRD testing to inform refining and adapting therapy over time by tracking residual disease,” said Rick Baehner, Senior Vice President and Chief Medical Officer, Precision Oncology, Abbott Cancer Diagnostics.
In later‑stage or recurrent breast cancer, comprehensive molecular profiling such as the OncoExTra® test may help inform treatment planning and clinical trial consideration.
But more data do not automatically create better care. The key questions for health systems are practical: which patients are appropriate, when testing should occur, who interprets the result, and what action should follow. Without governance, innovation can add noise faster than clarity.
Breast cancer as a gateway to enterprise oncology
For health system leaders, breast cancer is more than a single disease pathway. It is often the proving ground for a broader oncology operating model. The same capabilities required to optimize breast cancer care—multidisciplinary coordination, order‑set governance, timely diagnostics, and reliable handoffs—are the capabilities needed to connect risk assessment and screening upstream with treatment selection, monitoring, and survivorship downstream.
That governance does not start with new technology. It starts with clarity: who defines eligibility, who owns the order, where results route in the EHR, what turnaround time is expected, and how exceptions are escalated. Breast cancer pathways are well suited for this work because volumes are high, stakeholders are already engaged, and variation across sites is visible and measurable.
In that sense, diagnosing and treating breast cancer is not just one phase of care. It is a gateway to the screening‑to‑survivorship model many health systems are working to build across oncology. Organizations that get this pathway right are not just improving one service line. They are building the operational discipline needed to scale coordinated, data‑informed cancer care across the enterprise.
To learn more about how health systems are approaching pathway discipline across precision oncology, visit https://www.exactsciences.com/health-systems/precision-oncology.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
